MicroRNA profiles following telmisartan treatment in pancreatic ductal adenocarcinoma cells

Persistent ID (NDL): info:ndljp/pid/12985065

Material type: 博士論文

Author: Yamana, Yoshimi

Publisher: -

Publication date: 2021-03-24

Material Format: Digital

Capacity, size, etc.: -

Name of awarding university/degree: 香川大学,博士（医学）

View All

Notes on use at the National Diet Library

本資料は、掲載誌(URI)等のリンク先にある学位授与機関のWebサイトやCiNii Dissertationsから、本文を自由に閲覧できる場合があります。

Notes on use

Note (General)：: Background: Panereatic ductal adenocarcinoma (PDAC) is the most devastating of all cancers with an extremely poor prognosis. It has few effective and ...

Search by Bookstore

Read this material in an accessible format.

View materials in accessible formats for people with print disabilities (1Type)

Search by Bookstore

Read in Disability Resources

Other Services
- テキストデータ check it on 国立国会図書館デジタルコレクション

Bibliographic Record

You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.

Digital

Material Type: 博士論文
Title: MicroRNA profiles following telmisartan treatment in pancreatic ductal adenocarcinoma cells
Author/Editor: Yamana, Yoshimi
Author Heading: Yamana, Yoshimi
Publication Date: 2021-03-24
Publication Date (W3CDTF): 2021-03-24
Alternative Title: 膵癌細胞へのテルミサルタン投与におけるMicroRNA発現プロファイル
Degree grantor/type: 香川大学
Date Granted: 2021-03-24
Date Granted (W3CDTF): 2021-03-24
Dissertation Number: 甲第777号
Degree Type: 博士（医学）
Text Language Code: eng
Alias of Author: 山名, 佳美
ヤマナ, ヨシミ
Subject Heading: Angiotensin II type 1 receptor blocker
cell cycle arrest
microRNA
pancreatic ductal adenocarcinoma
telmisartan
Target Audience: 一般
Note (General): Background: Panereatic ductal adenocarcinoma (PDAC) is the most devastating of all cancers with an extremely poor prognosis. It has few effective and reliable therapeutic strategies. Telmisartan, a widely used antihypertensive drug, is an angiotensin II type 1 (AT1) receptor blocker (ARB). Telmisartan inhibits cancer cell proliferation, but the underlying mechanisms in PDAC, remain unknown.
Material and Methods: In the present study, we evaluated the effects of telmisartan on human PDAC cell proliferation in vitro. We assessed the effects of telmisartan on human PDAC cells using the cell lines PK-1 and PANC-1.
Results: Tel misartan inhibited the proliferation of these cells via blockade of the GO to G1 cell cycle transition. This was accompanied by a strong decrease in cyclin 01. Telmisartan was also shown by receptor tyrosine kinase and angiogenesis arrays to reduce the phosphorylation of epidermal growth factor receptor (EGFR), and miRNA expression was markedly altered by telmisartan in PK-1 cells.
Conclusion: In conclusion, telmisartan inhibits human PDAC cell proliferation by inducing cell cycle arrest. Furthermore, telmisartan significantly altered miRNA expression in vitro. Taken together, our study demonstrated the therapeutic potential of telmisartan and provides molecular mechanistic insights into its anti-tumor effect on PDAC cells.
Persistent ID (NDL): info:ndljp/pid/12985065
https://dl.ndl.go.jp/pid/12985065
Collection: 障害者向け資料
Collection (Materials For Handicapped People:1): テキストデータ
Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文
https://dl.ndl.go.jp/collections/A00014
Acquisition Basis: 博士論文（自動収集）
Date Accepted (W3CDTF): 2023-09-01T22:11:29+09:00
Format (IMT): application/pdf
Access Restrictions: 国立国会図書館内限定公開
Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
Availability of remote photoduplication service: 可
Periodical Title (URI): https://kagawa-u.repo.nii.ac.jp/records/7343
Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション
https://dl.ndl.go.jp